Display ad
HomeHealthMedicineHormone Therapy May Reduce Death, Cancer Risk in Older Women

Hormone Therapy May Reduce Death, Cancer Risk in Older Women

Researchers printed the study covered in this summary on medRxiv.org as a preprint that has not but been peer reviewed.

Key Takeaways

Why This Matters

  • In 2002, adverse information concerning the Women’s Health Initiative (WHI) estrogen+progestin remedy (EPT) outcomes created lasting fears about hormone remedy (HT), regardless of later statistical corrections to the adverse outcomes and one other, less-publicized, WHI examine in 2004 figuring out a number of advantages for estrogen monotherapy.

Study Design

  • The researchers analyzed knowledge from 2007-2019 information of greater than 7 million ladies with Medicare protection aged 65 and older, of whom 15% used some sort of HT not less than as soon as throughout the examine interval.

  • The researchers categorised HT into estradiol alone; conjugated estrogen alone; progestin alone; estradiol and progestin mixed; conjugated estrogen and progestin mixed; and ethinyl estradiol progestin mixed. The examine reviewed three dose strengths in addition to routes together with oral, transdermal, vaginal, and injectable.

  • They used Cox regression evaluation to check the impact of every HT drug on the 13 outcomes included within the examine evaluation.

Key Results

  • Rates of demise occurred much less usually in ladies utilizing hormone remedy, 6.08/1000 affected person years, in contrast with a price of 12.93/1000 affected person years amongst these not utilizing hormone remedy. After adjustment for potential confounders the hazard ratio (HR) for mortality on hormone remedy was 0.80 in contrast with ladies not on hormone remedy.

  • Mortality threat reductions have been vital in contrast with no hormone remedy for each estradiol (hazard ratio [HR], 0.78) and conjugated estrogen (HR, 0.86).

  • In an evaluation by route of administration, vital mortality reductions occurred with vaginal (HR, 0.69), oral (HR, 0.89), and transdermal (HR, 0.78) formulations.

  • Treatment with estrogen with out progestin linked with vital reductions within the incidence of all cancers studied in contrast with no hormone remedy, together with breast (HR, 0.82), lung (HR, 0.87), endometrial (HR, 0.65), colorectal (HR, 0.86) and ovarian (HR, 0.83).

  • High-dose, however not low-dose, estrogen was related to a barely however considerably elevated threat for ischemic heart disease (HR, 1.03 and 0.98, respectively).

  • Both estrogen+progestin remedy and progestin monotherapy every considerably related to an elevated breast cancer threat (HR, 1.11 and 1.09, respectively).


  • Data availability began with ladies over 65 years.

  • The researchers trusted declare knowledge that could not be validated with chart evaluate.

  • This observational examine could not account for potential confounding elements corresponding to well being conduct.


This is a abstract of a preprint research study, “Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 7 million menopausal women over age 65: a retrospective observational study,” written by researchers on the National Library of Medicine, National Institutes of Health, Bethesda, Maryland, on medRxiv, supplied to you by Medscape. This examine has not but been peer reviewed. The full textual content of the examine will be discovered on medRxiv.org.

For extra Medscape Diabetes and Endocrinology information, observe us on Twitter and Facebook



Please enter your comment!
Please enter your name here

Most Popular